Abstract
There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Current Molecular Medicine
Title: Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB
Volume: 7 Issue: 3
Author(s): Kerstin J. Williams and Ken Duncan
Affiliation:
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Abstract: There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Export Options
About this article
Cite this article as:
Williams J. Kerstin and Duncan Ken, Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB, Current Molecular Medicine 2007; 7 (3) . https://dx.doi.org/10.2174/156652407780598575
DOI https://dx.doi.org/10.2174/156652407780598575 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Affinity Tags to Overcome Obstacles in Recombinant Protein Expression and Purification
Protein & Peptide Letters Cytotoxicity, Genotoxicity, Antioxidant Potential and Chemical Composition of Leaves of Campomanesia pubescens (Mart. ex DC.) O.Berg
Current Pharmaceutical Biotechnology Recent Progress in the Identification and Development of Anti-Malarial Agents Using Virtual Screening Based Approaches
Combinatorial Chemistry & High Throughput Screening Ceric Ammonium Nitrate Catalysed Stereoselective Synthesis of β-Aminoketones Using 3-Aryl-4-Formylsydnones
Letters in Organic Chemistry Anti-Tuberculosis
Current Bioactive Compounds 4-(4-((5-Amino-1,3,4-thiadiazol-2-yl)methoxy)phenyl)-1-((5-amino-1,3,4-thiadiazol-2-yl)methyl)-3-benzyl-1H-1,2,4-triazol-5(4H)-one: Synthesis, Characterization and Computational Studies
Letters in Organic Chemistry Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Current Pharmaceutical Design Editorial: Recent Advances in the Field of Kinases and Kinase Inhibitors
Current Pharmaceutical Design Insights into sRNA Genes Regulated by Two-Component Systems in the <i>Bacillus cereus</i> Group
Current Bioinformatics Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Vertebral Lesions from AIDS-Related Kaposi's Sarcoma
Current HIV Research Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery Development of Antibacterial Drugs by Targeting Toll-Like Receptors
Current Topics in Medicinal Chemistry Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design
Current Drug Targets Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology Ascorbic Acid: An Old Player with a Broad Impact on Body Physiology Including Oxidative Stress Suppression and Immunomodulation: A Review
Mini-Reviews in Medicinal Chemistry Shikimate Kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: Kinetics and Structural Dynamics of a Potential Molecular Target for Drug Development
Current Medicinal Chemistry Drug Repurposing: Translational Pharmacology, Chemistry, Computers and the Clinic
Current Topics in Medicinal Chemistry Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Recent Patents on Anti-Cancer Drug Discovery